Despite his injury, the Ukrainian refused to quit and took Golovkin the full twelve-round distance, forcing him to dig deep.

Callum Walsh has some heavy hitters with him on his team and they are being proved right all the time. One of them speaks after his MSG win.

The clamor is out for Saúl "Canelo" Alvarez vs. Gennady "Triple G" Golovkin, but it seems both camps are not yet ready for that big clash. One of the bright spots the Miami Heat can look up to these ...

San Antonio Spurs rookie Harrison Ingram finished with a triple-double on Tuesday in the G League, leading the Austin Spurs to a win over the Memphis Hustle. Ingram produced 17 points, 13 rebounds, 10 ...

Activating a third receptor, in principle, could lead to stronger weight-loss effects or additional cardiometabolic benefits. Lilly is pushing ahead in the clinical assessment of its triple-G agonist ...

This is the same mechanism as Eli Lilly’s next-generation “triple-G” drug retatrutide, which has so far appeared to be the most effective obesity drug in development. In a small early ...

UBT251 targets GLP-1, GIP, and a third hormone, glucagon, hence the name "triple G". Rival Eli Lilly (LLY.N), opens new tab is developing a similar drug, retatrutide, that has shown to help ...

(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

UBT251, a so-called “triple G” agonist, targets GLP-1, gastric inhibitory polypeptide (GIP) and glucagon. For comparison, Wegovy inhibits GLP-1 while Eli Lilly’s competitor Zepbound (tirzapetide) is a ...

No­vo Nordisk is not im­mune to the trend of seek­ing obe­si­ty as­sets from Chi­na-based biotechs, and the Dan­ish drug­mak­er will pay … ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion. Novo has ...